Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of extensive-stage small cell lung cancer (stage IV or too large for radiation).
- You must not have received any previous systemic treatment for extensive-stage disease.
- You must have at least one tumor that can be measured on a scan.
- You must be in good overall health with normal blood counts, kidney, and liver function.
- You must not have active autoimmune disease or an allergy to any of the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Hear when a new Lung Cancer, Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.